Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or significant improvement (> 70% reduction in cough severity measure) at · adults with subacute and chronic cough
1 finding from 1 review
Secondary outcomes · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or > 50% reduction in cough severity measure at · adults with subacute and chronic cough
1 finding from 1 review
Clinical cure · adults with subacute and chronic cough
1 finding from 1 review
Severity of cough (mean improvement score) · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in mean change in cough score Symptomatic cough severity measure as… compared with placebo (low certainty).
1 finding from 1 review
Proportion with adverse effects of treatment · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in proportion with adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Admission to hospital or death · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Resolution of symptoms · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Time to symptom resolution · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in symptom resolution: duration to symptoms resolved compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Serious adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Infections · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in infections compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
Effects of different inhaled corticosteroids on growth in children… may leads to higher linear growth velocity (cm/year) compared with beclomethasone (low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
It is very uncertain whether effects of different inhaled corticosteroids on growth in children… changes linear growth velocity (cm/year) compared with budesonide (very low certainty).
1 finding from 1 review
Change in height · children up to 18 years of age with persistent asthma
Effects of different inhaled corticosteroids on growth in children… probably leads to higher change in height (cm) over a period of time compared with budesonide (moderate certainty).
1 finding from 1 review
Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).
1 finding from 1 review